Mesothelioma in Younger Adults Linked to Genetic Risk Factors

About 3,300 people are diagnosed each year in the United States, and the average age at diagnosis is 70 to 75. Symptoms can resemble common respiratory conditions in younger adults, which may delay workup. A new study shows disease patterns in patients 50 years or younger that call for heightened diagnostic vigilance.

Memorial Sloan Kettering Cancer Center (MSK) conducted a retrospective analysis of 273 individuals diagnosed with diffuse pleural mesothelioma at or under 50 years of age who were treated at MSK between 1990 and 2023. Clinical records were reviewed alongside tumor tissue when available. Findings were published in JCO Precision Oncology on March 18, 2026.

The cohort included a disproportionately high number of females relative to historical distributions for this disease. Fewer patients reported known asbestos exposure, particularly among those younger than 35 years. Seventy percent of patients had a family history of cancer, most commonly breast, lung, or colon cancer. Inherited alterations in BAP1 and BRCA1/BRCA2 were noted to appear to increase risk in younger patients. Investigators also cited possible environmental contributors in New York City, including exposure to carcinogens after the September 11, 2001 World Trade Center collapse, while emphasizing that the underlying reasons for rising recognition in younger adults remain unclear.

For clinical laboratories and oncology teams, MSK highlights the role of comprehensive genetic testing of tumor tissue in younger patients. Identifying a specific driver gene may inform the use of targeted therapies, repurposed agents approved for other cancers, and discussion of clinical trial options. The authors underscore that early detection is critical and that clinicians should consider mesothelioma when younger patients present with persistent cough, chest pain, or dyspnea that does not respond to antibiotics. Treatment strategies may also differ for younger adults; in selected cases, careful monitoring may be appropriate due to prolonged latency.

“If we find a specific gene causing their cancer, they may be able to have a targeted therapy directed at that gene mutation. In some cases, we can repurpose a drug that is approved for another type of cancer. It also helps us discuss novel clinical trials and treatment options if we find a gene that can be targeted,” said Michael Offin, MD, thoracic medical oncologist at Memorial Sloan Kettering Cancer Center.

Related Links
Memorial Sloan Kettering Cancer Center